FGFR4 and hepatocellular carcinoma: Gatekeeper mutations in the kinase domain (V550) and hinge-1 (C552) of FGFR4 are acquired as a mechanism of resistance to fisogantib, a selective FGFR4 inhibitor, in HCC [41].